Sustained low efficiency dialysis is non-inferior to continuous renal replacement therapy in critically ill patients with acute kidney injury

A comparative meta-analysis

Sultan Al Dalbhi, MDa, b, Riyadh Alorf, MDa, Mohammad Alotaibi, MDa, Abdulrahman Altheaby, MD, b, Yasser Alghamdi, MDc, Hadeel Ghazal, MDa, Hussam Almuzaini, MDa, Helmy Negm, MDa

Abstract

**Background:** Critically ill adults with acute kidney injury (AKI) experience considerable morbidity and mortality. This systematic review aimed to compare the effectiveness of continuous renal replacement therapy (CCRT) versus sustained low efficiency dialysis (SLED) for individuals with AKI.

**Methods:** We carried out a systematic search of existing databases according to standard methods and random effects models were used to generate the overall estimate. Heterogeneity coefficient was also calculated for each outcome measure.

**Results:** Eleven studies having 1160 patients with AKI were included in the analyses. Meta-analysis results indicated that there was no statistically significant difference between SLED versus continuous renal replacement therapy (CRRT) in our primary outcomes, like mortality rate (rate ratio [RR] 0.67, 95% confidence interval [CI] 0.44–1.00; P = .05), renal recovery (RR 1.08, 95% CI 0.83–1.42; P = .56), and dialysis dependence (RR = 1.03, 95% CI 0.69–1.53; P = .89). Also, no statistically significant difference was observed for between SLED versus CRRT in the secondary outcomes: that is, length of intensive care unit stay (mean difference –0.16, 95% CI –0.56–0.22; P = .41) and fluid removal rate (mean difference –0.24, 95% CI –0.72–0.24; P = .32). The summary mean difference indicated that there was a significant difference in the serum phosphate clearance among patients treated with SLED and CRRT (mean difference –1.17, 95% CI –1.90 to –0.44, P = .002).

**Conclusions:** The analysis indicate that there was no major advantage of using continuous renal replacement compared with sustained low efficiency dialysis in hemodynamically unstable AKI patients. Both modalities are equally safe and effective in treating AKI among critically ill patients.

**Abbreviations:** AKI = acute kidney injury, CCRT = continuous renal replacement therapy, EDD = extended daily dialysis, GFR = glomerular filtration rate, ICU = intensive care unit, IHD = intermittent hemodialysis, MOOSE = meta-analysis of observational studies in epidemiology guideline, RCTs = randomized controlled trials, RR = rate ratio, RRT = renal replacement therapy, SLED = sustained low efficiency dialysis, SLEDD = sustained low efficiency daily dialysis.

**Keywords:** acute kidney injury, continuous renal replacement therapy, hemodynamic instability, intensive care, meta-analysis, sustained low efficiency dialysis

1. Introduction

Acute kidney injury (AKI) is a new term for acute renal failure which is defined as a sudden, sustained decline in glomerular filtration rate (GFR), which is usually associated with uremia and a decline in urine output. Renal replacement therapy (RRT) is required for patients having severe AKI. It has been estimated that the mortality rate among AKI patients requiring RRT who were admitted in the intensive care unit (ICU) is 50% to 70%. [1] Continuous renal replacement therapy (CRRT) was introduced...
in 1977 with the intention of improving homeostasis among hemodynamically unstable patients having resistance to anti-diuretics. This treatment modality has been suggested to provide superior hemodynamic and cardiovascular stability owing to hypothermia, which increased venous return and blood pressure when compared with intermittent hemodialysis. Another variant of CRRT is pump-driven continuous veno-venous hemofiltration which provides for higher ultrafiltration rates and thereby, higher doses can be achieved by supplementing it with typical CRRT. However, owing to cost issues related with CRRT as it required sterilized solution bags for substitution fluids or dialysates, the concept of extended daily dialysis (EDD) was developed. EDD uses conventional dialysis machine, and the treatment time lasts for about 8 hours allowing for slower fluid and toxin removal. Furthermore, the introduction of sustained low-efficiency dialysis (SLED) has been considered as a major breakthrough in renal replacement therapy. SLED utilizes a single-batch dialysis system with on line dialysate production, which enables it to replace expensive and complex dialysis processes requiring operation by dialysis nurses. It has been reported that SLED provide similar outcomes in terms of urea removal when compared with CRRT. This technology is also known as prolonged intermittent renal replacement therapy as technologically, it is a hybrid of CRRT and intermittent hemodialysis (IHD). There are various synonyms for this technology like sustained low efficiency daily dialysis (SLEDD), sustained low efficiency daily dial-filtration, EDD, slow continuous dialysis, go slow dialysis, and accelerated veno-venous hemofiltration.

It has been documented in the literature that although CRRT is a conventional and more preferred treatment modality, its high costs makes it unavailable and inaccessible to the patients who need them. This motivated the development of hybrid techniques like SLEDD which is both cost effective as well as have similar efficacy to that of CRRT. Individual studies, both observational as well as randomized controlled trials have been conducted among ICU patients to compare these 2 treatment modalities. But owing to small sample sizes of individual studies, and different methodologies utilized by them for measuring outcome variables, none of these studies have adequate power to provide concrete evidence as to which of the treatment modalities is better.

Hence, the question remains regarding the effectiveness of the 2 RRT techniques, that is, CRRT versus SLED. A number of systematic reviews and meta-analysis of studies on intermittent RRT modalities have been carried out, but they did not adequately compare the effectiveness of CRRT versus SLED. Schneider et al reviewed the rate of dialysis dependence among patients on intermittent RRT modalities collectively. Zhang et al review compared CRRT and SLED in 2015, but in their analysis they separated the results of randomized controlled trials (RCTs) and observational studies resulting in inconclusive findings. Also, there was evidence of publication bias from the selected studies as many of the included studies were not available online and were from China. Furthermore, the review by Nash et al in 2017 compared all the existing 3 modalities of RRT but they limited their study selection to RCTs only and very few outcome parameters were assessed.

Therefore, we carried out the present review to compare the efficacy of CRRT versus SLED by including both RCTs and prospective observational studies, and by considering all the outcome measures pertaining to survival, and various clinical and biochemical parameters among critically ill patients suffering from acute kidney injury and hemodynamic instability.

2. Aim
To compare clinical (renal and survival) and biochemical outcomes among critically ill patients with acute kidney injury and hemodynamic instability treated with CRRT and SLED.

3. Objectives
3.1. Primary objective
1. To compare in-hospital and ICU mortality rates among critically ill patients with acute kidney injury and hemodynamic instability treated with CRRT and SLED.
2. To compare renal outcomes (dialysis dependence and renal recovery posttreatment) for the above stated treatment modalities among critically ill patients with acute kidney injury and hemodynamic instability.

3.2. Secondary objective
1. To compare secondary outcomes like ICU length of stay, solutes clearance rate, and fluid removal rate among the same group of patients.

4. Null hypothesis
1. There is no difference in the renal and mortality outcome among critically ill-patients having acute kidney injury and hemodynamic instability treated with CRRT and SLED.
2. There are no differences for the secondary outcomes among these patients treated with CRRT as compared with SLED.

5. Methodology
We have done this meta-analysis as per the standard guidelines of Cochrane Collaboration. We used the preferred reporting items for systematic reviews and meta-analyses and meta-analysis of observational studies in epidemiology (MOOSE) to report a systematic review and meta-analysis of RCTs and observational studies (235, 26).

5.1. Study population/Exposure Group
Critically ill patients having acute kidney injury and hemodynamic instability.

5.2. Interventions to be compared
CRRT versus SLED.

5.3. Outcome measures
1. In-hospital and ICU mortality rates.
2. Renal outcome: kidney recovery, and dialysis dependence.
3. Secondary outcomes like ICU length of stay, solutes clearance rate, and fluid removal rate (L/24h).
5.4. Operational definitions

CRRT: It included all synonymous terms like continuous hemofiltration or continuous hemodialfiltration or continuous hemodialysis, being done 24 hours a day.

SLED: Similarly, we planned to include all studies which described extended session of >6 hours but <24 hours of hemodialysis or hemodiafiltration. It included all synonyms that is, prolonged intermittent renal replacement therapy, SLED, SLED-f, SLEDD, EDD, slow continuous dialysis, go slow dialysis, and accelerated veno-venous hemofiltration which have been described in the introduction section.[7]

5.5. Study selection

5.5.1. Types of study. We decided to include all randomized controlled trials as well as prospective cohort studies which compared the outcomes of CRRT and SLED among critically ill-patients of AKI and hemodynamic instability from January 1995 up to December 2018.

5.5.2. Study selection. The following data sources were searched for all RCTs and prospective cohort-control studies:

a. PubMed,
b. EMBASE/ Excerpta Medica,c. Cochrane Central Register of Controlled Trials,
d. Google Scholar,
e. Reference lists.

Search strategies were independently designed and performed by 2 separate investigators. We used the following MeSH terms or keywords in different combinations and permutations for searching studies from year January 1995 to December 2018 in advanced PubMed search:

“Acute kidney injury,” “Acute kidney failure,” “hemodialysis,” “hemodiafiltration,” “dialysis,” “Continuous renal replacement therapy,” and “slow low efficiency dialysis and its synonyms.”

The search strategies described above provided a list of studies. The titles and abstracts of all the retrieved studies were screened independently by 2 authors. The irrelevant studies were discarded in the first attempt. Later on, the full-text version of the shortlisted studies was analyzed for the presence of a measurable outcome variable in terms of:

a. ICU or in-hospital mortality rates among two treatment groups.
b. Renal recovery rates.
c. Dialysis dependence rates among 2 groups.
d. Fluid removal rates.
e. Solute clearance rate (serum uric acid, serum creatinine, and serum phosphate)
f. Length of hospital/ICU stay.

We did not pose any restrictions on the language of the articles as most of the articles could be translated by the google translate tool; which most of the journals supported for language conversion. But at the end, we chose only full text articles where detailed data were available for extraction and analysis.

5.6. Data extraction

We extracted the following study features: first author, publication year, country, number of participants in each group, RRT modalities, number of deaths in each group, number of patients who had 100% kidney recovery, number of patients who were dependent on dialysis after treatment, fluid removal rates in L/24h in both treatment group, length of stay in ICU (days), and clearance rates of serum uric acid, serum creatinine, and serum phosphate among 2 groups. Outcomes reported in ≥2 articles were extracted for meta-analysis.

5.7. Quality assessment of studies

Internal validity of randomized controlled trials (RCTs) was assessed using the Cochrane Risk of Bias Tool while the quality of prospective cohort studies was assessed using the Newcastle-Ottawa scale.

5.8. Data analysis

Extracted data were entered and analyzed using Revman 5.3. Before the analysis, data were standardized into equivalent units. For dichotomous variables such as mortality, rates in the experimental (SLEDD/EDD) and control (CRRT) groups were expressed as rate ratio and 95% CI. For continuous variables such as length of ICU stay, fluid removal, and biochemical parameters, mean difference, and 95% CI were calculated for each study. Heterogeneity in the studies was evaluated using the Cochrane Q test and I² statistic to assess the degree of inter study variation. I² values of 0% to 24.9%, 25% to 49.9%, 50% to 74.9%, and 75% to 100% were considered as having no, mild, moderate, and significant thresholds for statistical heterogeneity.

6. Results

6.1. Study selection

The combined literature search identified around 5497 studies which contained the MeSH terms either in the title or abstract. After reviewing the title, we included 98 studies for abstract review. Finally, only 11 studies matched the inclusion criteria. The excluded studies were on the basis of various reasons described in Fig. 1.

The eligible studies were conducted from year 2004 till 2017. Of the 11 eligible studies, 6 were RCTs,[11,15,17,18,23,28] and 5 were prospective cohort studies[11,14,20,21] carried out among different parts of the world as depicted in Table 1. The total population covered was 1160. Of these, 530 (46%) individuals were allocated to SLEDD and rest were treated using the CRRT modality. The mean age of the study participants varied from 50 to 70 years. The proportion of men among the study population varied from 63% to 75%.

6.2. Assessment of methodological quality

The risk of bias among the RCT’s included in the analysis are as summarized in Table 2. Of the 5 RCT’s, 3 had low risk for random sequence generation;[15,17,28] while bias for allocation concealment was low in only one study.[28] There was high risk for blinding bias for almost all the included studies except the study by Kielstein et al,[28] which had low risk of this bias. Incomplete outcome data bias was high in only one study.[23] Selective outcome reporting bias was also high in one study that was by Mishra et al.[21]

Similarly, Newcastle-Ottawa scale was used to assess bias among prospective cohort studies as presented in Table 3.
6.3. Outcome 1: mortality

Two types of mortality data were extracted from eligible studies; in-hospital and ICU mortality. In-hospital mortality was reported by 4 studies. [11,13,15,17] Their meta-analysis showed that there was no significant difference in the in-hospital mortality rates among patients treated with SLED compared with CRRT (RR = 0.67 [0.44–1.00], P = .05, I² = 0%). This is shown in Fig. 2. There was no significant heterogeneity among the selected studies.

Similarly, the ICU mortality rate was reported by 9 studies. [13–15,17,18,20–22,28] The meta-analysis of these studies showed 0% heterogeneity and there was no significant difference in the ICU mortality rates among 2 treatment modalities as shown in Fig. 3 (RR = 0.88, 95% CI = 0.77–1.02, P value = .08, I² = 0%).

6.4. Outcome 2: dialysis dependence

Figure 4 described the meta-analysis of 5 studies that assessed for dialysis dependence among the 2 treatment modalities. [11,13,15,17,22] The analysis revealed 0% heterogeneity and showed that there was no significant difference for rates of

Table 1

| First author, year | Design           | Country     | N  | CRRT | SLED | Mean age | Sex (% males) | Main outcomes                                      |
|--------------------|------------------|-------------|----|------|------|----------|--------------|-----------------------------------------------------|
| Kielstein, 2004    | RCT              | Germany     | 39 | 19   | 20   | 50.5     | 62.9         | Mortality, fluid removal, biochemical clearance      |
| Kumar 2004         | Prospective cohort | United States | 54 | 28   | 26   | 52       | 63%          | Mortality, kidney recovery, RRT dependence, ICU days. |
| Abe 2010           | RCT              | Japan       | 60 | 30   | 30   | 68.7     | 65           | Mortality, kidney recovery, RRT dependence, ICU days |
| Wu 2010            | Prospective cohort | Taiwan    | 101 | 63   | 38   | 67.3/67.5 | 66.6/63.1 | Mortality                                          |
| Abe 2011           | RCT              | Japan       | 50 | 25   | 25   | 65.9     | 66           | Mortality, kidney recovery, RRT dependence, ICU days |
| Schwenger 2012     | RCT              | Germany     | 232| 117  | 115  | 66.2     | 67.7         | Mortality, fluid removal, ICU days, biochemical clearance |
| Badawy 2012        | RCT              | Egypt       | 80 | 40   | 40   | 47.5     | 65           | Mortality, fluid removal, RRT dependence, ICU days, biochemical clearance |
| Chen 2014          | Prospective cohort | China     | 107| 55   | 52   | 59.27/59.83 | NR          | Mortality                                         |
| Sun 2014           | Prospective cohort | China     | 145| 65   | 80   | 67.78/68.59 | 75.3/73.7  | Mortality                                          |
| Kitchlu 2015       | Prospective cohort | Canada     | 232| 158  | 74   | 62.1/60.6 | 59.5/67.6   | Mortality, RRT dependence, clinical deterioration   |
| Mishra 2017        | RCT              | India       | 60 | 30   | 30   | 47.8/49  | 70          | Fluid removal                                      |

CRRT = continuous renal replacement therapy, ICU = intensive care unit, RCT = randomized controlled trials, RRT = renal replacement therapy, SLED = sustained low efficiency dialysis.
Table 2
Bias matrix among randomized controlled trial studies.

| Parameters of bias in RCTs | Kielstein 2004 | Abe 2010 | Abe 2011 | Schwenger 2012 | Badawy 2012 | Mishra 2017 |
|---------------------------|----------------|----------|----------|----------------|-------------|-------------|
| Sequence generation       | L              | UC       | L        | L              | UC          | H           |
| Allocation concealment    | L              | UC       | UC       | UC             | UC          | UC          |
| Blinding of patients and personnel | L              | H        | H        | H              | H           | H           |
| Blinding of outcome assessors | L              | UC       | UC       | UC             | UC          | UC          |
| Incomplete outcome data   | L              | L        | L        | L              | H           | H           |
| Selective outcome reporting | UC             | L        | L        | L              | L           | H           |
| Other sources of bias     | L              | UC       | UC       | UC             | UC          | UC          |

L=low risk of bias, H=high risk of bias, RCT=randomized controlled trials, UC=unclear risk of bias.

Table 3
Bias matrix for prospective cohort studies.

| Parameters of NOS scale | Kumar 2004 | Wu 2010 | Chen 2014 | Sun 2014 | Kitchlu 2015 |
|-------------------------|------------|---------|------------|----------|--------------|
| Representatives of exposed cohort | L          | L       | L          | L        | L            |
| Selection of non-exposed cohorts | L          | L       | L          | L        | L            |
| Ascertainment of exposure | L          | L       | L          | L        | L            |
| Outcome of interest not present | L          | L       | L          | L        | L            |
| Comparability of cohort (age wise) | H          | L       | L          | L        | UC           |
| Comparability of cohort (severity of illness wise) | H          | L       | L          | L        | UC           |
| Assessment of outcome | L          | L       | L          | L        | L            |
| Was follow-up long enough | L          | L       | L          | L        | L            |
| Adequacy of follow up of cohorts | UC         | L       | L          | L        | L            |

L=low risk of bias, H=high risk of bias, UC=unclear risk of bias.

Figure 2. Forest plot comparing in-hospital mortality among patients of acute kidney injury treated by SLED versus CRRT. CRRT=continuous renal replacement therapy, SLED=sustained low efficiency dialysis.

Figure 3. Forest plot comparing ICU mortality among critically ill-patients of acute kidney injury and hemodynamic instability. ICU=intensive care unit.
dialysis dependence posttreatment among patients treated with SLED compared with CRRT (RR=1.03, 95% CI=0.69–1.53, \(P=.89\), \(I^2=0\%\)).

### 6.5. Outcome 3: renal recovery

The summary risk ratio of 6 studies\([13–15,18,20,21]\) that assessed for renal recovery indicated that there was no significant difference in the renal recovery status among patients treated with SLED compared with CRRT (RR=1.08, 95% CI=0.83–1.42, \(P=.56\)). However, as shown in Fig. 5, there was significant heterogeneity among the selected studies for this outcome measure (\(\tau^2=0.07\), \(\chi^2=13.42\), df=5, \(P=.02\); \(I^2=63\%\)).

### 6.6. Outcome 4: length of stay in ICU

The summary mean difference of 5 studies\([11,13,15,17,18]\) that assessed length of stay in the ICU indicated that there was no significant difference in the ICU stay among patients treated with SLED versus CRRT (mean difference =–0.16, 95% CI =–0.56–0.22, \(P=.41\)). As shown in Fig. 6, there was significant heterogeneity among the selected studies for this outcome measure (\(\tau^2=0.13\), \(\chi^2=13.96\), df=4, \(P=.007\); \(I^2=71\%\)).

### 6.7. Outcome 5: fluid removal

The summary mean differences in fluid removal among 4 selected studies\([17,18,23,28]\) indicated that there was no significant differ-

---

**Figure 4.** Forest plot of comparing dialysis dependence among patients of acute kidney injury and hemodynamic instability.

**Figure 5.** Forest plot of comparing renal recovery among critically ill-patients of acute kidney injury and hemodynamic instability.

**Figure 6.** Forest plot of comparison in length of stay in ICU among Acute Kidney Injury patients treated by SLED vs CRRT. CRRT = continuous renal replacement therapy, ICU = intensive care unit, SLED = sustained low efficiency dialysis.
ence in the fluid removal rates (L/24h) among patients treated with SLED compared with CRRT (mean difference = -0.24, 95% CI = -0.72–0.24, \( P = .32 \)). There was significant heterogeneity among the selected studies for this outcome measure (\( \tau^2 = 0.18, \chi^2 = 14.14, df = 3, P = .003, I^2 = 79% \)) as shown in Fig. 7.

### 6.8. Outcome 6: biochemical clearance

The summary mean difference of 3 selected studies indicated that there was no significant difference in the clearance rates for serum creatinine, and serum uric acid among patients treated with SLED versus CRRT as shown in Figs. 8 and 9. However, there was significant heterogeneity among the selected studies for this outcome measure.

The summary mean difference of 2 selected studies indicated that there was a significant difference in the serum phosphate clearance among patients treated with SLED and CRRT (mean difference = -1.17, 95% CI = -1.90 to -0.44, \( P = .002 \)).[17,28] There was significant heterogeneity among the selected studies for this outcome measure (\( \tau^2 = 0.21, \chi^2 = 3.68, df = 1, P = .06, I^2 = 73% \)) as indicated in Fig. 10.

### 7. Discussion

This review identified 11 original studies that compared the performance of SLED versus CRRT among >1160 patients with AKI and hemodynamic instability.[11,13–15,17,18,20–23,28] When we analyzed data from RCTs and prospective cohort studies, we found that patients who received SLED as an initial RRT modality for AKI had a similar risk of death compared with those who initially received CRRT. Similarly, there were no significant differences in kidney recovery, dialysis dependence, ICU length of stay (in days), and fluid removal with SLED in comparison to CRRT. Also, SLED showed similar efficacy to CRRT in laboratory results for serum urea, and serum creatinine during RRT. However, the efficacy of SLED was statistically significant in clearing serum phosphates level as compared with CRRT.
In the past, many systematic reviews and meta-analysis have compared the performance of IHD with CRRT. They concluded that the mortality risk was similar for IHD and CRRT treated individuals. Both of these treatment modalities had their own advantages and disadvantages. These factors led to the development of hybrid technology of SLED. Researchers have tried to carry out independent studies to compare the performance of SLED and CRRT using varying methodologies of RCTs and cohort study designs. But due to limited sample sizes, different methodologies, subject selection and outcome assessment, it became very difficult to reach any firm conclusions on the performance of these two modalities. These limitations informed the need to conduct this systematic reviews and meta-analysis.

Our study builds on previous published meta-analyses by Zhang et al.\textsuperscript{24} Nash et al.\textsuperscript{25} and Tonelli et al.\textsuperscript{30} We found 4 and 9 studies that reported on in-hospital mortality and ICU mortality rate, respectively. The analyses indicate that there were no statistically significant differences for the pooled results of in-hospital mortality and ICU mortality rates comparing patients who received CRRT compared with SLED. This suggests that in a setting where economic costs is a major consideration, the cost-effective RRT modality (SLED) should be the option of choice. Other advantages of performing SLED over CRRT includes: its prolonged nature, subjects who were given treatment with CRRT seem to decrease the need for dialysis compared with SLED.\textsuperscript{33,40,41} Therefore, the dialysate phosphate concentration during fluid withdrawal during conditions of serious illness.\textsuperscript{37,38}

Our analyses further revealed that there was no significant difference in the clearance rates of serum creatinine and serum uric acid among patients treated with SLED versus CRRT. However, the summary mean difference indicated that there was a significant difference in the serum phosphate clearance rates among patients treated with SLED compared with CRRT. Due to its prolonged nature, subjects who were given treatment with SLED usually require daily monitoring and often supplementation of potassium and phosphorus.\textsuperscript{33,40,41} Our finding is consistent with the results of previous studies which reported that hypophosphatemia may occur in a significant proportion of subjects treated with SLED compared with those treated with CRRT.\textsuperscript{33,40,41} Therefore, the dialysate phosphate concentration in individuals receiving SLED needs to be adjusted accordingly and the patients may require supplementation.\textsuperscript{33,40,41}

Our study has some limitations. This is a purely statistical meta-analysis using published data of each study selected. This is per se may be a possible cause of bias. The number of studies and the number of patients included in the meta-analysis is not high. Therefore, study number, different study designs with small sample sizes can be considered limitations of our review. Third, one of the strongest limitations of this study is the fact that the studies included in the review were conducted in different periods of time, in different countries, with different methodologies and the only data in which we have access are the published reports from the various studies. An individual patient data meta-analysis may improve upon these limitations. Finally, one major limitation is the inclusion of all studies in the review despite some of the studies having low quality (as indicated by bias matrix for RCTs and prospective cohort studies) due to scarcity of existing literature.

However, based on the current meta-analysis and the reviews done in the past, we can draw some cautious conclusions. First, these 2 modalities of renal replacement do not produce different outcomes in adults with AKI and hemodynamic instability. Second, the overall risk of mortality was reduced in patients receiving SLED but this finding might have been diluted due to sample sizes of individual studies and variations in the design of the studies with shorter follow-up periods.

Hence, future research should focus on well-planned RCTs or cohort studies with longer duration of follow up along with

| Study or Subgroup | SLED Mean | SLED SD | CRRT Mean | CRRT SD | Total Mean | Total SD | Total Weight | Std. Mean Difference IV, Random, 95% CI |
|-------------------|-----------|---------|-----------|---------|-------------|----------|-------------|---------------------------------------|
| Kielstein 2004    | 3.7       | 0.3     | 20        | 4.2     | 19          | 0.3      | 39.6%       | -1.63 [-2.37, -0.90]                  |
| Schwenger 2012    | 0.88      | 0.34    | 115       | 1.18    | 117         | 0.35     | 60.4%       | -0.67 [-1.14, -0.60]                  |
| Total (95% CI)    | 135       | 100%    | 136       | 100%    |             |          |             | -1.17 [-1.96, -0.44]                  |

**Figure 10.** Forest plot of comparing serum phosphate among patients with acute kidney injury treated SLED versus CRRT. CRRT = continuous renal replacement therapy, SLED = sustained low efficiency dialysis.
address of key outcome measures like mortality, and renal outcomes along with biochemical profile. Hence, it can be concluded that there is no clear advantage for using continuous renal replacement in the hemodynamically unstable patient. Albeit, CRRT is more costly than SLED. Both the modalities are equally safe and effective in treating AKI among critically ill patients. Hence, SLED can be used in place of CRRT to cut costs as both have same efficacy.

Author contributions
Conceptualization: Sultan Al Dalbhi.
Data curation: Riyadh Alorf, Mohammad Alotaibi.
Formal analysis: Sultan Al Dalbhi, Mohammad Alotaibi.
Funding acquisition: Riyadh Alorf, Mohammad Alotaibi.
Investigation: Riyadh Alorf, Mohammad Alotaibi.
Methodology: Sultan Al Dalbhi.
Project administration: Sultan Al Dalbhi.
Resources: Riyadh Alorf, Abdulrahman Altheaby, Yasser Alghamdi.
Software: Abdulrahman Altheaby, Yasser Alghamdi, Hadeel Ghazal, Helmy Negm.
Supervision: Abdulrahman Altheaby.
Validation: Sultan Al Dalbhi.
Visualization: Abdulrahman Altheaby, Yasser Alghamdi.
Writing – original draft: Hadeel Ghazal, Hussam Almuzaini.
Writing – review & editing: Hussam Almuzaini, Helmy Negm.

References
[1] Brown JR, Rezaee ME, Marshall EJ, Matheny ME. Hospital mortality in the United States following acute kidney injury. J Biomed Res Int 2016;2016:4278579.
[2] Janapala RN, Jayaraj JS, Fathima N, et al. Continuous glucose monitoring versus self-monitoring of blood glucose in type 2 diabetes mellitus: a systematic review with meta-analysis. Cureus 2019;1:6:e5634.
[3] Finkel KW, Podoll AS. Complications of continuous renal replacement therapy. Semin Dial 2009;22:155–9.
[4] Gasparovic V, Filipovic-Grcic I, Merkler M, Pisl Z. Continuous renal replacement therapy (CRRT) or intermittent hemodialysis (IHD)—what is the procedure of choice in critically ill patients? Ren Fail 2003;25:855–62.
[5] Berbee A, Richardson R. Sustained low-efficiency dialysis in the ICU: cost, anticoagulation, and solute removal. Kidney Int 2006;70:963–8.
[6] Lu RH, Yan YC, Gu Y, Xue J, Chen N, Zhang W. Effects of CVVH and SLED in patients with acute renal failure after liver transplantation. J Shanghai Jiaotong Univ (Med Sci) 2008;8:27.
[7] Joannidis M. Good-bye CRRT, here comes SLED?,... no not so fast! Crit Care 2012;16:167.
[8] Kumar VA, Craig M, Depner TA, Yeun JY. Extended daily dialysis: a new approach to renal replacement for acute renal failure in the intensive care unit. Am J Kidney Dis 2000;36:294–300.
[9] Lonnemann G, Floege J, Kliem V, Brunkhorst R, Koch KM. Extended daily veno-venous high-flux haemodialysis in patients with acute renal failure and multiple organ dysfunction syndrome using a single path batch dialysis system. Nephrol Dial Transplant 2000;15:1189–93.
[10] NxStage Medical, Inc. Prolonged intermittent renal replacement therapy. Changing the face of dialysis in the ICU. Available at: https://www.nxstage.com/hcp/therapies/prrt/ (accessed on February 6, 2019).
[11] Kumar VA, Yeun J, Depner T, Don B. Extended daily dialysis vs. continuous hemodialysis for ICU patients with acute renal failure: a two-year single center report. Int J Artif Organs 2004;27:371–9.
[12] Baldwin I, Bellomo R, Naka T, Koch B, Fealy N. A pilot randomized controlled comparison of extended daily dialysis with filtration and continuous veno-venous hemofiltration: fluid removal and hemodynamic. Int J Artif Organs 2007;30:1083–9.
[13] Abe M, Okada K, Suzuki M, et al. Comparison of sustained hemodiafiltration with continuous venovenous hemodiafiltration for the treatment of critically ill patients with acute kidney injury. Artif Organs 2010;34:331–8.
[14] Wu VC, Wang CH, Wang WJ, et al. NSAR5 Study Group.Sustained low-efficiency dialysis versus continuous veno-venous hemofiltration for postsurgical acute renal failure. Am J Surg 2010;199:466–76.
[15] Abe M, Maruyama N, Matsumoto S, et al. Comparison of sustained hemofiltration with continuous venous hemofiltration in patients with acute kidney injury. Int J Nephrol 2011;2011:432094.
[16] Shin YB, Cho JH, Park JY, et al. Sustained low-efficiency dialysis as an alternative therapy to continuous renal replacement therapy in critically ill patients with acute kidney injury. Korean J Nephrol 2011;30:516–22.
[17] Schwenger V, Weigand MA, Hoffmann O, et al. Sustained low efficiency dialysis using a single-pass batch system in acute kidney injury—are randomized interventional trial: the REAnal Replacement Therapy Study in Intensive Care Unit PatiEnts. Crit Care 2012;16:R140.
[18] Badawy SS, Hassan AR, Samir EM. A prospective randomized comparative pilot trial on extended daily dialysis versus continuous venovenous hemodiafiltration in acute kidney injury after cardiac surgery. Egypt J Cardiothorac Anesth 2013;7:69–73.
[19] Schneider AG, Bellomo R, Bagshaw SM, et al. Choice of renal replacement therapy modality and dialysis dependence after acute kidney injury: a systematic review and meta-analysis. Intensive Care Med 2013;39:987–97.
[20] Chen X. Sustained low-efficiency dialfiltration for diabetic nephropathy patients with acute kidney injury. Med Princ Pract 2014;23:119–24.
[21] Sun Z, Ye H, Shen X, Chao H, Wu X, Yang J. Continuous venovenous hemofiltration versus daily dialysis in patients with septic acute kidney: a retrospective cohort study. Crit Care 2014;18:R70.
[22] Kitchlu A, Adhikari N, Burns KE, et al. Outcomes of sustained low efficiency dialysis versus continuous renal replacement therapy in critically ill adults with acute kidney injury: a cohort study. BMC Nephrol 2015;16:127.
[23] Mishra SB, Azim A, Prasad N, et al. A pilot randomized controlled trial of comparison between extended daily hemodialysis and continuous veno-venous hemodialysis in patients of acute kidney injury with septic shock. Indian J Crit Care Med 2017;21:262–7.
[24] Zhang L, Yang J, Eastwood GM, Zhu G, Tanaka A, Bellomo R. Extended daily dialysis versus continuous renal replacement therapy for acute kidney injury: a meta-analysis. Am J Kidney Dis 2015;66:322–30.
[25] Nash DM, Przech S, Wald R, O’reilly D. Systematic review and meta-analysis of renal replacement therapy modalities for acute kidney injury in the intensive care unit. J Crit Care 2017;41:138–44.
[26] Group DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000;283:2008–12.
[27] Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264–9.
[28] Kielstein JT, Kretschmer U, Ernst T, et al. Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study. Am J Kidney Dis 2004;43:329–42.
[29] Kovacs B, Sullivan KJ, Hirsemath S, Patel RV. Effect of sustained low efficiency dialysis versus continuous renal replacement therapy on renal recovery after acute kidney injury in the intensive care unit: a systematic review and meta-analysis. Nephrology (Carlton) 2017;22:343–53.
[30] Tonelli M, Manns B, Wiebe N, et al. Continuous Renal Replacement Therapy in Adult Patients with Acute Renal Failure: Systematic Review and Economic Evaluation. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health; 2007.
[31] Marshall MR, Ma T, Galler D, Rankin AP, Williams AB. Sustained low-efficiency dialfiltration (SLEDD-f) for critically ill patients requiring renal replacement therapy: towards an adequate therapy. Nephrol Dial Transplant 2004;19:877–84.
[32] Bagshaw SM, Darmon M, Ostermann M, et al. Current state of the art for renal replacement therapy in critically ill patients with acute kidney injury. Intensive Care Med 2017;43:841–54.
[33] Sethi SK, Sinha R, Jha P, et al. Feasibility of sustained low efficiency dialysis in critically sick pediatric patients: a multicentric retrospective study. Hemodial Int 2018;22:228–34.
[34] Pannu N, Klarenbach S, Wiebe N, Manns B, Tonelli M. Renal replacement therapy in patients with acute renal failure: a systematic review. JAMA 2008;299:793–805.
[35] Rabindranath K, Adams J, Macleod A, Muirhead N. Intermittent versus continuous renal replacement therapy for acute renal failure in adults. Cochrane Database Syst Rev 2007;3:CD003773.

[36] Prowle JR, Bellomo R. Continuous renal replacement therapy: recent advances and future research. Nat Rev Nephrol 2010;6:521–9.

[37] de Souza Oliveira MA, Dos Santos TOC, Monte JCM, et al. The impact of continuous renal replacement therapy on renal outcomes in dialysis-requiring acute kidney injury may be related to the baseline kidney function. BMC Nephrol 2017;18:150.

[38] Tandukar S, Palevsky PM. Continuous renal replacement therapy: who, when, why, and how. Chest 2019;155:626–38.

[39] Schetz M, Gunst J, Van den Berghe G. The impact of using estimated GFR versus creatinine clearance on the evaluation of recovery from acute kidney injury in the ICU. Intensive Care Med 2014;40:1709–17.

[40] Marshall MR, Golper TA, Shaver MJ, Alam MG, Chatoth DK. Sustained low-efficiency dialysis for critically ill patients requiring renal replacement therapy. Kidney Int 2001;60:777–85.

[41] Albino BB, Balbi AL, Abrao JM, Ponce D. Dialysis complications in acute kidney injury patients treated with prolonged intermittent renal replacement therapy sessions lasting 10 versus 6 hours: results of a randomized clinical trial. Artif Organs 2015;39:423–31.